Yeast Infection is also known as candidiasis. Candidiasis is an infection caused by numerous types of yeast called Candida. The most common type of yeast causing infection is Candida albicans. This yeast is normally present on the skin, in the intestines and vagina, but under normal conditions it doesn’t cause infection. However, sometimes it can develop into an infection of the mouth, vagina or skin due to weak immune response, unhygienic conditions, and other factors. The Global Yeast Infection Market is expected to grow at a CAGR of 5.2% during the forecasted period.
Yeast infection can occur due to many reasons such as weak immunity, unhygienic conditions, and presence of a conducive environment for the growth of the associated microbes. In addition to infants, people suffering from diabetes, obesity, hypothyroidism, inflammatory disorders are also prone to catching yeast infection. The global yeast infection market is majorly driven by increasing prevalence of autoimmune diseases, continuously increasing geriatric population, and increasing number of patients suffering from HIV.
According to the Joint United Nations Programme on HIV and AIDS (UNAIDS), by the end of 2015, approximately 36.7 million people worldwide were suffering from HIV/AIDS , out of which 1.8 million were children below 15 years. Moreover, rising demand for antifungal drugs and government support for research & development have fuelled the market growth. However, side effects of the treatment may hinder the growth of the market.
Global Yeast Infection Market – Key Players
Some of the key players in yeast infection market are
- Scynexis (US)
- Synmedic Laboratories(India)
- Merck & Co., Inc. (US)
- Astellas (Japan)
- Bayer AG (Germany)
- Mentis Pharma Ltd. (India)
- Abbott (US)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- Sanofi (France)
- ALLERGAN (Ireland)
- AstraZeneca (UK)
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/4228 .
Global Yeast Infection Market – Competitive Analysis
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Bayer AG, headquartered in Germany, focuses on research, development, production, and distribution of medical products for the prevention, diagnosis and treatment of fungal diseases.
Canespro is treatment method from Bayer AG for fungal infections occurred in nails. Canespro softens the infected part of the nails only.
June, 2017: Pfizer Inc. received exclusive commercialization rights in Europe for Cresemba, which is a novel treatment for potentially life-threatening fungal infections in immunocompromised patients
August, 2016: Pfizer Inc. announced its entry into an agreement with AstraZeneca to acquire the development, and commercialization rights to its late-stage small molecule anti-infectives business
November, 2014: Sanofi and its subsidiary Genzyme has announced the approval of Lemtrada by U.S. Food and Drug Administration (FDA)
Merck develops and markets broad portfolio of 300,000 products across the globe. The company is a market leader in pharmaceutical, and biotechnological having strong presence in various parts of the world.
January, 2015: The Merck has acquire Cubist Pharmaceuticals. This acquisition will help the company to increase its revenue, and establish stronger position in hospital acute care
February, 2016: AureoGen Biosciences Inc., signed an agreement with Merck for the application of AureoGen’s proprietary chemistry and compounds in the development of medicines for infectious disease, which include systemic fungal infections.
The global yeast infection market is very competitive in nature. The companies are focusing on the new product developments. Whereas, some major has adopted strategies of acquisitions and strategic alliances for the growth of the market.
Merck & Co., Inc. holds a healthy share of the global yeast infection market owing to the Cancidas, Noxafil and VETRANAL which are some of the top selling drugs worldwide.
Global Yeast Infection Market – Segmentation
The global yeast infection market is segmented on the basis of pathogen, types, treatment, and end users. On the basis of pathogens, the market is segmented into Candida albicans, Candida glabrata, Candida rugosa, and others.
On the basis of types, the market is categorized into vaginal yeast infection, skin yeast infection, throat yeast infection, and others.
On the basis of treatment, the market is segmented into drug treatment and surgery. Drug treatment is further classified into cream, ointment, tablet, and suppository.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers and others.
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/4228 .
Major Table of Content
1 Report Prologue
2 Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar